Ersodetug

Phase 3Small molecule

RRezolute

Ersodetug is one of 46 small molecule programs targeting Hyperinsulinism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperinsulinismActive, not recruiting

HypoglycemiaActive, not recruiting

HyperinsulinismPhase 3

Active, not recruiting

HypoglycemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

77 competitors in Hypoglycemia

#DrugCompanyPhaseTrials

Avelox

Narcan

2 3

Glucagon

XXeris Pharmaceuticals

Phase 3

14 4

Ilaris

Novartis

Phase 3

1 5

Detemir

Eli Lilly

Approved

1 6

Zegalogue

Zealand Pharma

Phase 3

4 7

Jardiance

Boehringer Ingelheim

Phase 3

3 8

Sandostatin

Sun Pharma

Phase 3

2 9

Glibenclamide

Novo Nordisk

Phase 3

1 10

MS Contin

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Hyperinsulinism

NCT06881992

Clinical

Trials by Indication[1]

Hypoglycemia1 trial

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Available·RRezolute··NCT07262970

Hyperinsulinism1 trial

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

Recruiting·RRezolute·Phase 3·NCT06881992·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ersodetug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ersodetug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ersodetug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rezolute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRezolute

Ersodetug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hypoglycemia1 trial

Hyperinsulinism1 trial

References

Drug Info

Quick Facts

Related News